Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes.

OBJECTIVE To investigate the association between treatment-induced change in continuous glucose monitoring (CGM) time in range (TIR) and albuminuria in persons with type 1 diabetes (T1D) treated with sensor-augmented insulin pumps (SAP). RESEARCH DESIGN AND METHODS Twenty-six out of 55 participants with albuminuria and multiple daily injection therapy (25% females; 51 [46–63] years of age; glycated hemoglobin A1c (HbA1c) 75 [68–88] mmol/mol [9.0% (8.4–10.4%)]; and urinary albumin-to-creatinine ratio (UACR) 89 [37–250] mg/g) were in a randomized controlled trial assigned to SAP therapy for 1 year. Anthropometrics, CGM data, and blood and urine samples were collected every 3 months. RESULTS Mean change (95% CI) in percentage of TIR (%TIR) was 13.2% (6.2; 20.2), HbA1c was −14.4 (−17.4; −10.5) mmol/mol (−1.3% [−1.6; −1.0]), and UACR was −15% (−38; 17) (all P CONCLUSIONS In this longitudinal study, treatment-induced increase in %TIR was significantly associated with decrease in albuminuria in T1D.